Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (131-140 of 313) with videos related to

Pageof 32
Sort By:
European Journal of Haematology|March 7, 2026
Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell TherapySantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
Frontiers in Oncology|July 5, 2021
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia PopulationsDomenico Maisano, Enrico Iaccino, Alessandro D'Ambrosio, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 24, 2018
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapiesErnesto Vigna, Annamaria Petrungaro, Anna Perri, et al.
Expert Opinion on Pharmacotherapy|November 19, 2019
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphomaFortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, et al.
Blood|April 5, 2003
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresAnna Guarini, Gianluca Gaidano, Francesca Romana Mauro, et al.
Frontiers in Immunology|July 29, 2022
Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-ε and -ωAlessandra Pierangeli, Massimo Gentile, Giuseppe Oliveto, et al.
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
Cytotherapy|July 20, 2015
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patientsMassimo Martino, Anna Grazia Recchia, Tiziana Moscato, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
Pageof 32

Showing results (131-140 of 313) with videos related to

Sort By:
Pageof 32
European Journal of Haematology|March 7, 2026
Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell TherapySantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
Frontiers in Oncology|July 5, 2021
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia PopulationsDomenico Maisano, Enrico Iaccino, Alessandro D'Ambrosio, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 24, 2018
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapiesErnesto Vigna, Annamaria Petrungaro, Anna Perri, et al.
Expert Opinion on Pharmacotherapy|November 19, 2019
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphomaFortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, et al.
Blood|April 5, 2003
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresAnna Guarini, Gianluca Gaidano, Francesca Romana Mauro, et al.
Frontiers in Immunology|July 29, 2022
Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-ε and -ωAlessandra Pierangeli, Massimo Gentile, Giuseppe Oliveto, et al.
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
Cytotherapy|July 20, 2015
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patientsMassimo Martino, Anna Grazia Recchia, Tiziana Moscato, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
Pageof 32